2177-PUB: Improved Time-in-Range and Glycemic Variability in Adults with Type 1 Diabetes: An Analysis of 12-Week Flash Glucose Monitoring Data from a Multicenter Prospective Trial

Abstract

Aims: Studies have demonstrated that CGM can improve HbA1C and reduce glucose variability in individuals with type 1 diabetes (T1D). We aim to assess the efficacy of flash glucose technology on glycemic accuracy control in T1D by lifestyle and/or medication modification and to use the CGM time in range (TIR) as outcomes of measures. Methods: The program is a multicenter, prospective, RCT enrolled adults from 5 Chinese diabetes centers. Individuals were eligible to participate if they had T1D and were deemed technically capable of using flash glucose technology. All participants had no experience with Flash before participating the study and received the education of diabetes self-care at baseline. Based on the glucose reports, dietary, excise and insulin therapy changes were made by self-care behaviors. Data from 153 adults who using flash glucose monitoring for 12 weeks were analyzed. Results: After 153 participants who had no experience with flash used flash for 12 weeks, HbA1C was reduced from (7.96± 1.78) % at baseline to (7.54±1.20) % at 12 weeks (P<0.05). An increase in TIR70-180 was from 51.49% to 54.68%. The TAR >250 drop from 12.65% to 7.77%, with a concurrent decrease in TBR54-69 from 9.96% to 8.31% and TBR<54 from 4.21% to 3.19%(P<0.005). And the CV reduced from 39.5% to 37.3% in these patients(P<0.05). Conclusion: T1D patients who had no experience with flash achieved a better glycemic profile from the flash glucose monitoring. Flash glucose technology is useful for improving glycemic control of T1D patients by changes to patient’s lifestyle and/or insulin therapy. Disclosure L. Guo: None. M. Zhang: None. H. Kuang: None. Y. Li: None. X. Xiao: None. X. Jia: None. T. Yang: None.